Nuveen Asset Management LLC Grows Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Nuveen Asset Management LLC lifted its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 27.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,683,208 shares of the biotechnology company's stock after purchasing an additional 361,086 shares during the quarter. Nuveen Asset Management LLC owned 0.55% of Iovance Biotherapeutics worth $12,456,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. AlphaQuest LLC increased its holdings in Iovance Biotherapeutics by 63.6% in the 4th quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company's stock worth $34,000 after buying an additional 1,794 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in Iovance Biotherapeutics in the 4th quarter worth about $36,000. One68 Global Capital LLC bought a new stake in Iovance Biotherapeutics in the 4th quarter worth about $74,000. Quarry LP bought a new stake in Iovance Biotherapeutics in the 4th quarter worth about $74,000. Finally, Fullcircle Wealth LLC bought a new stake in Iovance Biotherapeutics in the 4th quarter worth about $74,000. 77.03% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on IOVA shares. Truist Financial downgraded Iovance Biotherapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 12th. Baird R W downgraded Iovance Biotherapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 9th. Barclays cut their price target on Iovance Biotherapeutics from $5.00 to $4.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Robert W. Baird cut their price target on Iovance Biotherapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Friday, February 28th. Finally, HC Wainwright cut their price target on Iovance Biotherapeutics from $32.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, Iovance Biotherapeutics currently has an average rating of "Hold" and an average price target of $13.30.

Iovance Biotherapeutics Stock Up 1.2%

NASDAQ IOVA traded up $0.02 during trading hours on Wednesday, reaching $1.75. The company's stock had a trading volume of 13,082,387 shares, compared to its average volume of 8,708,703. The firm's 50-day moving average price is $2.87 and its 200-day moving average price is $5.29. Iovance Biotherapeutics, Inc. has a 1 year low of $1.64 and a 1 year high of $12.51. The company has a market capitalization of $584.38 million, a price-to-earnings ratio of -1.17 and a beta of 1.06.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.11). The firm had revenue of $49.32 million for the quarter, compared to analysts' expectations of $83.40 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The firm's revenue was up 6795.1% on a year-over-year basis. During the same period last year, the company earned ($0.42) earnings per share. Equities research analysts anticipate that Iovance Biotherapeutics, Inc. will post -1.24 EPS for the current fiscal year.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.